Medtronic Plc (MDT) has a strong backing from institutional investors, who reportedly own about
85%-87% of the company's shares. The company is reported to be raising its
dividend to $0.70, and Medtronic's financial results for the
third and fourth quarter of
fiscal 2024 financial results have been showcased. However, the company's stock seem to be facing difficulties as it has been
underperforming and facing losses. Furthermore, Medtronic's CFO,
Karen Parkhill, has announced her departure from the company. The company has made product developments like
MiniMed 780G system which shared positive data, and it has also gained
FDA approval for its Evolut TAVR system for treating symptomatic severe aortic stenosis. Despite recent
share price drops and losses faced by investors in the past three years, Medtronic's future is seen as bright by some with one offer suggesting a 35% undervaluation.
Medtronic Plc MDT News Analytics from Sat, 04 Nov 2023 03:03:08 GMT to Sun, 14 Jul 2024 16:28:08 GMT -
Rating -3
- Innovation 2
- Information 5
- Rumor -2
